Other Mediators At Age-Related Macular Degeneration

Abstract

Objective Insome patients, even if anti-VEGF therapy is repeatedly administered at certain intervals, no response is obtained. Therefore, a search for new treatment methods has arisen. The aim of this study was to investigate the relevance of mediators such as Erythropoietin, Interleukin 17, and Angiotensin2,which are all involved in proliferation, apoptosis, oxidative stress, and inflammation in age-related macular degeneration. Metods EPO, IL-17, and Angiotensin 2 levels were evaluated by examining the blood samples of patients who did not have any systemic disease or chronic eye disease except Age-related Macular Degeneration (AMD). Results The patients were divided into 3 groups. Groups 1,2, and 3 were determined as the control group, dry type group, and neovascular type group respectively. For the purpose of this study, erythropoietin, interleukin 17, angiotensin2 were examined in the blood samples of patients. As a result of the analyses, a statistically significant difference was detected between the groups in terms of EPO, IL-17, and Angiotensin 2. Conclusion If the relationship between many factors related to age-related macular degeneration can be clearly defined, the perspective on treatment may change, especially in treatment-resistant patients.

Keywords

• age related macular degeneration
• erythropoietin
• interleukin 17
• angiotensin 2

References

1. Referans1. Fleckenstein M, Keenan TDL, Guymer RH et.all. Age-related macular degeneration. Nature Reviews Disease Primer 2021; 7(1): 31. doi: 10.1038/s41572-021-00265-2.
2. Referans2. Mettu, P.S., M.J. Allingham, S.W. Cousins. Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities. Progress in Retinal and Eye Research 2021; May; 82:100906. doi: 10.1016/j.preteyeres.2020.100906
3. Referans3. Iglicki M, David Pérez González DP, Loewenstein A et al. Longer-acting treatments for neovascular age-related macular degeneration—present and future. Eye 2021; 35(4): 1111-1116. doi: 10.1038/s41433-020-01309-9
4. Referans4. Cho YK Dae-Hun, Park DH, Jeon IC. Medication Trends for Age-Related Macular Degeneration. International journal of molecular sciences 2021; 22(21): 11837. doi: 10.3390/ijms222111837
5. Referans5. Lin JB, Omar Halawa OA, Husain D et al. Dyslipidemia in age-related macular degeneration. Eye 2022; Feb;36(2): 312-318. doi: 10.1038/s41433-021-01780-y
6. Referans6. Armento A, Ueffing M, and S.J. Clark. The complement system in age-related macular degeneration. Cellular and molecular life sciences : CMLS 2021; 78(10): 4487-4505. doi: 10.1007/s00018-021-03796-9
7. Referans7. Feizi S, Ansari MA, Karimian F et al. Use of erythropoietin in ophthalmology: a review. Surv Ophthalmol 2022; Mar-Apr;67(2): 427-439 doi: 10.1016/j.survophthal.2021.06.002
8. Referans8. Güler M, Aydın S, Urfalıoğlu S et al. Aqueous humor heat-shock protein 70, periostin, and irisin levels in patients with pseudoexfoliation syndrome. Arq Bras Oftalmol 2020; 83(5):378-382. doi: 10.5935/0004-2749.20200046

9. Referans9. Wang H, Zhang M, Zhou H et al. Salusin-β Mediates High Glucose-Induced Inflammation and Apoptosis in Retinal Capillary Endothelial Cells via a ROS-Dependent Pathway in Diabetic Retinopathy. Diabetes Metab Syndr Obes 2021; 14: 2291-2308. doi:10.2147/DMSO.S301157
10. Referans10. Biswal MR, Wang Z, Paulson RJ et al. Erythropoietin Gene Therapy Delays Retinal Degeneration Resulting from Oxidative Stress in the Retinal Pigment Epithelium. Antioxidants (Basel, Switzerland) 2021; 10(6): 842. doi: 10.3390/antiox10060842
11. Referans11. Thomas CJ, Mirza RG , Gill MK. Age-Related Macular Degeneration. Med Clin North Am 2021; 105(3):473-491. doi: 10.1016/j.mcna.2021.01.003
12. Referans12. Girolamo F, Coppola C, Ribatti D et al. Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis. Acta neuropathologica communications 2014; 2(1):1-17. doi: 10.1186/s40478-014-0084-z.
13. Referans13. Rex TS, Allocca M, Domenici L et al. Systemic but not intraocular Epo gene transfer protects the retina from light-and genetic-induced degeneration. Molecular Therapy. 2004; 10(5):855-861. doi: 10.1016/j.ymthe.2004.07.027
14. Referans14. Caprara C, Britschgi C, Samardzija M et al. The erythropoietin receptor is not required for the development, function, and aging of rods and cells in the retinal periphery. Molecular Vision 2014; 20:307.
15. Referans15. Rex TS, Kasmala L, Bond WS et al. Erythropoietin slows photoreceptor cell death in a mouse model of autosomal dominant retinitis pigmentosa. PLoS One 2016; 11(6): e0157411. doi: 10.1371/journal.pone.0157411.
16. Referans16. Rex TS, Wong Y, Kodali K et al. Neuroprotection of photoreceptors by direct delivery of erythropoietin to the retina of the retinal degeneration slow mouse. Experimental Eye Research 2009; 89(5): 735-740. doi: 10.1016/j.exer.2009.06.017.
17. Referans17. Li Y, Zhou Y. Interleukin-17: The Role for Pathological Angiogenesis in Ocular Neovascular Diseases. The Tohoku Journal of Experimental Medicine 2019; 247(2): 87-98. doi: 10.1620/tjem.247.87
18. Referans18. Pongsachareonnont P, Mak MYK, Hurst CP et al. Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment. Clinical ophthalmology (Auckland, N.Z.) 2018; 12: 1877-1885. 10.2147/OPTH.S171636.
19. Referans19. Singh A, Subhi Y, Krogh Nielsen M et al. Systemic frequencies of T helper 1 and T helper 17 cells in patients with age-related macular degeneration: A case-control study. Scientific Reports 2017; 7: 1-9. doi: 10.1038/s41598-017-00741-4
20. Referans20. Wu Q, Liu B, Yuan L et al. Dysregulations of follicular helper T cells through IL-21 pathway in age-related macular degeneration. Molecular Immunology 2019; 114: 243-250. doi: 10.1016/j.molimm.2019.07.028
21. Referans21. Nassar K, Grisanti S, Elfar E et al. Serum cytokines as biomarkers for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2015; 253(5): 699-704. doi: 10.1007/s00417-014-2738-8.
22. Referans22. Chen J, Wang W, Li Q. Increased Th1/Th17 Responses Contribute to Low-Grade Inflammation in Age-Related Macular Degeneration. Cell Physiol Biochem. 2017; 44(1): 357-367. doi: 10.1159/000484907
23. Referans23. Shin JI, Bayry J. A role for IL-17 in age-related macular degeneration. Nat Rev Immunol 2013; 13(9): 701. doi: 10.1038/nri3459-c1
24. Referans24. Wheeler-Schilling TH, Kohler K, Sautter M et al. Angiotensin II receptor subtype gene expression and cellular localization in the retina and non‐neuronal ocular tissues of the rat. European Journal of Neurosciencen 1999;11(10): 3387-3394. doi: 10.1046/j.1460-9568.1999.00787.x.
25. Referans25. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacological reviews 2000; 52(1): 11-34.
26. Referans26. Praddaude F, Cousins SW, Pêcher C et al. Angiotensin II-induced hypertension regulates AT1 receptor subtypes and extracellular matrix turnover in mouse retinal pigment epithelium. Experimental eye research 2009; 89(1):p. 109-118. doi: 10.1016/j.exer.2009.02.020
27. Referans27. Pons M, Cousins SW, Alcazar O et al. Angiotensin II-induced MMP-2 activity and MMP-14 and basigin protein expression are mediated via the angiotensin II receptor type 1-mitogen-activated protein kinase 1 pathway in retinal pigment epithelium: implications for age-related macular degeneration.The American journal of pathology 2011; 178(6): 2665-2681. doi: 10.1016/j.ajpath.2011.02.006
28. Referans28. Nagai N, Oike Y, Izumi-Nagai K et al. Angiotensin II Type 1 Receptor–Mediated Inflammation Is Required for Choroidal Neovascularization. Arterioscler Thromb Vasc Biol 2006; 26: 2252-2259. doi: 10.1161/01.ATV.0000240050.15321.fe
29. Referans29. Choudhary R, Kapoor MS, Singh A et al. Therapeutic targets of renin-angiotensin system in ocular disorders. Journal of current ophthalmology 2016; 29(1): 7-16. doi: 10.1016/j.joco.2016.09.009.